Answers are grounded in this paper and cite their sources.
Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by erythrocytosis. Therapeutic phlebotomy is widely used in PV care, aimed to lower hematocrit levels to <45%. This study aimed to assess the real-world burden of phlebotomy and patient quality of life (QoL). Data were drawn from the Adelphi Real World PV Disease Specific Programme™, a cross-sectional survey with retrospective data collection, in patients with PV and their treating physicians in the U.S. between August 2025 and February 2026. Thirty-nine physicians reported data for 160 patients; 97 had received a phlebotomy in the 12 months prior to the survey (23 frequent phlebotomy; 74 infrequent phlebotomy). Most (91.5%) had uncontrolled hematocrit levels, defined as ≥1 test ≥45%, and no significant association was found between hematocrit control and phlebotomy frequency. Fatigue was commonly reported as a phlebotomy side effect (69.1%) and as a symptom (19.6%), and the median PROMIS Fatigue score was 56.6 (48.1, 61.1). Median activity impairment on the WPAI was 30.0% (20.0, 65.0). Current treatments, including phlebotomy (with or without cytoreductive therapy), may not adequately control hematocrit or symptoms, and impair QoL. This highlights a need for treatment strategies that offer control over hematocrit and symptoms while improving QoL.
No takes yet. Share an insight, caveat, or question.
Pettit et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: